The findings indicated that Fc-OPG did not inhibit osteoblastic bone lesions of LuCaP 23.1 cells, but decreased the growth of tumor cells determined by the reduction of the serum prostate-specific antigen (PSA) [30]. The gene discussed is TNFRSF11B; the disease is neoplasm.